API maker Hovione moves into particle design

Portuguese API maker Hovione has invested in crystal design and particle size reduction to the nanoscale size and amorphose solid dispersion so it can offer those capabilities for the lab or commercial scale-up. The company tells in-PharmaTechnologist that it was hearing from customers that they needed the capability to handle "highly potent compounds." The publication points out that Hovione has been putting attention on solubility solutions. Last year, it struck a deal with Particle Sciences ($PSI) that allowed it to offer scale-up manufacturing services for solubilization processes developed by PSI. Story | More

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.